News

Past returns aren't guaranteed to repeat, but investors could still see huge upside.

Fed rate hikes, stubborn inflation and higher borrowing costs have pushed investors to care more about balance sheet strength than headline stories. That shift can reward stocks with solid cash flows while leaving weaker businesses exposed to the same news. This article cuts through the noise by focusing on quality. You will see three large cap stocks from our screener that appear better positioned to handle the Fed’s latest move. The three stocks below are just a starting sample from this...

nLIGHT has delivered a strong multi year share price run, and the question now is whether that performance lines up with what its sales can reasonably support. With the stock recently closing at US$38.43, investors face a simple but important query about how much revenue they are actually paying for. Over the past 3 years the share price has climbed about 273.1%, which puts a lot of weight on whether nLIGHT's current sales footprint can shoulder that kind of move. The business leans heavily...

On September 4, RTX Corporation (NYSE:RTX) announced that its Pratt & Whitney business was investing $25 million to expand its manufacturing facility in Niepołomice, Poland. The site produces complex tubular assemblies for both military and commercial engines. The expanded facility will begin operations in 2028 and create over 120 jobs. Niepołomice already delivers precision components […]

SpaceX’s reported decision to restrict new Falcon 9 commercial bookings beyond 2028 could create an opening for Neutron as Starship takes over future traffic.

On September 4, the U.S. Department of War (DoW) announced a $336,112,000 Navy contract for Huntington Ingalls Industries, Inc. (NYSE:HII) to advance procurement of long-lead materials for the construction of the future USS William J. Clinton (CVN 82). Work on the program will be executed in Newport News, Virginia, with completion anticipated by March 2039. […]

Doctors are exploring whether weight-loss drugs could also treat conditions such as endometriosis and Crohn’s disease.

Its performance this year has been underwhelming, but its long-term appeal is strong.

JPMorgan Chase & Co. (NYSE:JPM) said it plans to place more than $750 billion through 2035 to increase U.S. housing supply and support homeownership, with the Wall Street Journal covering the pledge as part of its broader American Dream Initiative. The commitment, nearly 40% more than the bank’s housing-related capital deployment over the prior decade, […]

Key Stats for Axon StockWednesday’s Performance: 6%52-Week Range: $339 to $792Valuation Model Target Price: Around $706Implied Upside: 56%What Happened?Axon Enterprise stock rebounded about 6% to $468 per share on Wednesday, one session after plunging nearly 10% to $442 following the announcement of a $1 billion offering of 0% convertible senior notes due 2031. Shares then fell about 3% to $454 on Thursday, leaving investors to weigh Axon’s strong operating momentum against concerns around dilut

Cuban noted a major irony that nobody in the industry has called out.

Coca-Cola Co. plans to invest $10 billion in U.S. infrastructure from 2026 through 2030 as the beverage company expands its production and distribution network. The investment will cover new or expanded production, distribution and office facilities across the country, including...

It reached a legal settlement with a business partner.

On September 8, 2026, the Wall Street Journal reported GameStop Corp. (NYSE:GME) second-quarter net income of $298.7 million, up from $168.6 million a year earlier, even as revenue fell to $790.2 million from $972.2 million. The video-game retailer raised its full-year adjusted EBITDA outlook to more than $650 million from a prior target of more […]

Palantir Technologies (PLTR) is back in focus after a cluster of AI focused partnerships with Method Security, NVIDIA and Nebius, raising fresh questions about how these deals might influence the stock’s long term narrative. Recent trading reflects that story taking hold. Palantir Technologies has a 7 day share price return of 6.22% and a 90 day share price return of 37.14%. However, the 1 year total shareholder return is slightly down at 0.45%, while the 3 year total shareholder return is...

SentinelOne has enjoyed a strong rebound in recent years, yet over a 5 year stretch long term holders are still looking at a deep drawdown. With the stock now trading around US$23.19 and sentiment lifted by its role in AI security, the live question is whether that price can be supported by the cash flows the business is expected to generate. Over 5 years the share price return is down 61.9%, which puts the focus squarely on whether the current valuation is now more closely aligned with what...

Bullish (NYSE:BLSH) has drawn fresh attention after a sharp daily gain of 8.8%, adding to a one-month move of 41.8% and a 3-month return of 44.9%. For context, Bullish shares trade at US$34.91 and recent momentum has been strong, with a 30 day share price return of 41.8% and a 90 day gain of 44.9%. However, the 1 year total shareholder return is still down 46.8%, which hints at sentiment recovering from a much weaker period. Scan beyond Bullish's rebound and size up other fast movers with...

Trane Technologies has been a powerful wealth creator over the past few years, and the recent pullback in the share price raises a simple question for investors who still own or are considering the stock. Are the cash flows behind this HVAC and climate solutions business strong enough to support where the market is pricing it today? Over the past 5 years, Trane Technologies has delivered a total return of 142.3%, which puts a lot of investor expectations into focus when you try to line that...

Banks are racing to issue stablecoins after fighting them for years. Payment experts from Triple-A, ChangeNOW, Infinia, and StraitsX explain what businesses actually gain.

Perhaps to the surprise of some, a few non-technology companies have seen wildly strong performances YTD, with their lower-beta nature providing a nice shield against volatility.

It signed a deal for the future deployment of as many as 25,000 vehicles.

Capital One Financial (NYSE:COF) CEO Richard Fairbank said the company continues to see consumer strength across its portfolio, with credit performance, spending trends and bank balances remaining resilient despite concerns about inflation, energy prices and broader economic uncertainty. Speaking a

An anonymous trader’s $7.19 million short position on the S&P 500 was fully liquidated on Hyperliquid as the market rebounded.

On September 8, 2026, CNBC reported that Novartis’ failed pelacarsen trial has raised the stakes for rival experimental cholesterol drugs from Amgen Inc. (NASDAQ:AMGN) and Eli Lilly and Company (NYSE:LLY), both of which are racing to prove that lowering lipoprotein(a), or Lp(a). It can meaningfully reduce heart attacks and strokes. Analysts said Amgen’s olpasiran faces […]

A day after the Federal Reserve’s first interest-rate increase in three years, stocks ended the day sharply higher. The rally reflected a reassessment from Wall Street, which had been fairly unmoved in the initial hours following the Fed’s move. Having slept on the hike, Wall Street apparently felt better this morning.

On September 3, 2026, CNBC reported that Microsoft Corporation (NASDAQ:MSFT)’s Xbox division will impose monthly time limits on cloud gaming for Game Pass subscribers starting in November, ending years of unlimited access. Game Pass Ultimate subscribers are capped at 15 hours per month, Premium subscribers at 10 hours, and Essential subscribers at 5 hours. Microsoft […]

Amazon advocates for thorough testing and public-private oversight over hasty AI deployments.

On September 9, 2026, Reuters reported that Meta Platforms, Inc. (NASDAQ:META) rolled out Muse, a long-touted AI agent that can autonomously send emails, sell a car, and book travel on a person’s behalf, despite internal concerns among Meta’s own employees that the technology mismanages access to sensitive personal data. The agent is modeled on the […]

On September 7, 2026, Reuters reported that Novo Nordisk A/S (NYSE:NVO) halted two additional trials of its experimental cardiovascular drug ziltivekimab, further denting the Danish drugmaker’s efforts to diversify beyond its blockbuster obesity and diabetes franchise. The move follows a July disclosure that ziltivekimab failed to reduce major adverse cardiovascular events in a late-stage trial. […]

It's launching not one, but two new fundraising efforts.